{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:41Z","timestamp":1777934741182,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_20030"],"award-info":[{"award-number":["MC_PC_20030"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_20051"],"award-info":[{"award-number":["MC_PC_20051"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_20058"],"award-info":[{"award-number":["MC_PC_20058"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_20059"],"award-info":[{"award-number":["MC_PC_20059"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V015737\/1"],"award-info":[{"award-number":["MR\/V015737\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W021390\/1"],"award-info":[{"award-number":["MR\/W021390\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"The Wellcome Trust","doi-asserted-by":"crossref","award":["222097\/Z\/20\/Z"],"award-info":[{"award-number":["222097\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["COV-LT-0009"],"award-info":[{"award-number":["COV-LT-0009"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NHS England"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gonadotropin-releasing hormone (GnRH) agonists are the most commonly used form of androgen deprivation therapy (ADT) for advanced prostate cancer, often prescribed with radiotherapy or chemotherapy. This study examined national trends in the prescribing of injectable GnRH agonists in England from 2015 to 2024, by formulation type and demographic factors (age, ethnicity, and deprivation). We hypothesised that the use of longer-acting formulations has been increasing over time, specifically during the COVID-19 pandemic when access to face-to-face appointments was limited, and that variation over time and by demographics could inform future service delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>With the approval of NHS England, we conducted a cohort study using the OpenSAFELY-TPP database of 24 million adults. Monthly prescription counts and rates (per 100,000 men with prostate cancer) were visualised over time. Generalised linear models were used to estimate the impact of the COVID-19 pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 390,265 men with prostate cancer (mean age 69.8 years, SD 13.5). Overall, 1,535,725 prescriptions were issued to 208,010 participants (53%). Monthly prescription counts increased by 40%, from 11,787 in 2015 to 16,697 in 2024, while rates declined from 8453 to 7721. During 2020\u20132021, prescribing of 1- and 3-monthly formulations decreased, whereas 6-monthly formulations increased from 437 per month (245 per 100,000 men) in 2019 to 755 (349 per 100,000 men) in 2024, an excess of 29%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Before the pandemic, 6-monthly formulations were rarely prescribed. Their uptake during the pandemic suggested a shift towards longer-acting formulations, reducing treatment burden. Declining GnRH rates may reflect earlier diagnosis and evolving treatment guidelines. Divergence between prescription counts and rates, and variation by demographic factors, reflected challenges faced by healthcare systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261436698","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:07:33Z","timestamp":1775743653000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Changing trends in androgen deprivation therapy prescribing for prostate cancer in England, 2015\u20132024"],"prefix":"10.1177","author":[{"given":"Gayasha","family":"Somathilake","sequence":"first","affiliation":[{"name":"University of Surrey"},{"name":"Early Diagnosis Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Wood","sequence":"additional","affiliation":[{"name":"University of Oxford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colm","family":"Andrews","sequence":"additional","affiliation":[{"name":"University of Oxford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Aning","sequence":"additional","affiliation":[{"name":"Bristol Urological Institute, North Bristol NHS Trust"},{"name":"Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Armes","sequence":"additional","affiliation":[{"name":"University of Surrey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Ford","sequence":"additional","affiliation":[{"name":"Brighton and Sussex Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kerrison","sequence":"additional","affiliation":[{"name":"University of Surrey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"MacKenna","sequence":"additional","affiliation":[{"name":"University of Oxford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Mehrkar","sequence":"additional","affiliation":[{"name":"University of Oxford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Rehman","sequence":"additional","affiliation":[{"name":"NHS Digital"},{"name":"London North West Healthcare NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Walker","sequence":"additional","affiliation":[{"name":"University of Oxford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4849-2430","authenticated-orcid":false,"given":"Agnieszka","family":"Lemanska","sequence":"additional","affiliation":[{"name":"Imperial College London"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6941a1"},{"key":"e_1_3_3_5_2","unstructured":"National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management guideline [NG131]. Published: May 2019. Updated: Dec 2021. www.nice.org.uk\/guidance\/ng131 Accessed Aug 2025."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/11205220-000000000-00000"},{"key":"e_1_3_3_7_2","unstructured":"Food and Drug Administration (FDA) US. Viadur\u00ae (leuprolide acetate implant). Label. Reference 2011; ID: 2888026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021088s025lbl.pdf. Accessed Aug 2025."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.101"},{"key":"e_1_3_3_9_2","first-page":"501","article-title":"Impact of COVID-19 pandemic on injection-based practice: report from an Italian multicenter and multidisciplinary survey","volume":"34","author":"Tenti S","year":"2022","unstructured":"Tenti S, et al. Impact of COVID-19 pandemic on injection-based practice: report from an Italian multicenter and multidisciplinary survey. Ann Ig 2022; 34: 501\u2013514.","journal-title":"Ann Ig"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/2374373521998842"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-093748"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00910.x"},{"key":"e_1_3_3_13_2","unstructured":"NICE UK (2024) Olaparib with abiraterone for untreated hormonerelapsed metastatic prostate cancer. Technology appraisal guidance (TA951). Published: 7 February 2024. www.nice.org.uk\/guidance\/ta951. Accessed August 2025."},{"key":"e_1_3_3_14_2","unstructured":"NPCA. 2024. https:\/\/www.npca.org.uk\/wp-content\/uploads\/2025\/01\/NPCA-State-of-the-Nation-Patient-Summary-2024.pdf."},{"key":"e_1_3_3_15_2","unstructured":"NICE UK (2021) Enzalutamide for treating hormone-sensitive metastatic prostate cancer. Technology appraisal guidance (TA712) Published: 7 July 2021. www.nice.org.uk\/guidance\/ta712. Accessed August 2025."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16305"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.18010.1"},{"key":"e_1_3_3_18_2","unstructured":"NHS England. Turnbull and Fry effect will save lives says NHS Chief. 2018. https:\/\/www.england.nhs.uk\/2018\/10\/turnbull-and-fry-effect-will-safe-lives-says-nhs-chief\/ Accessed June 2023."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"e_1_3_3_20_2","unstructured":"NHS Englan. 2025 Early cancer diagnosis in England reaches highest ever level. 2025. Available from https:\/\/www.england.nhs.uk\/2025\/01\/early-cancer-diagnosis-in-england-reaches-highest-ever-level\/. Last accessed March 2026."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"e_1_3_3_22_2","unstructured":"ICR The future of prostate cancer research: what could the next decade bring? https:\/\/www.icr.ac.uk\/news-features\/latest-features\/the-future-of-prostate-cancer-research-what-could-the-next-decade-bring accessed October 2024."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Andrews CD et al. OpenSAFELY: Representativeness of Electronic Health Record platform OpenSAFELY-TPP data compared to the population of England. medRxiv 2022: p. 2022.06.23.22276802.","DOI":"10.1101\/2022.06.23.22276802"},{"key":"e_1_3_3_25_2","article-title":"COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review","volume":"14","author":"Mostafavi Zadeh SM","year":"2023","unstructured":"Mostafavi Zadeh SM, et al. COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review. BMJ Supportive Palliative Care 2023; 14: spcare-2023\u2013004310.","journal-title":"BMJ Supportive Palliative Care"},{"key":"e_1_3_3_26_2","unstructured":"Somathilake G. PhD Thesis University of Surrey 2025."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2172281"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8452"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.5.334"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100904"},{"key":"e_1_3_3_31_2","unstructured":"The NHS England OpenSAFELY COVID-19 service - privacy notice. NHS Digital (Now NHS England). https:\/\/digital.nhs.uk\/coronavirus\/coronavirus-covid-19-response-information-governance-hub\/the-nhs-england-opensafely-covid-19-service-privacy-notice (accessed 4 July 2023)."},{"key":"e_1_3_3_32_2","unstructured":"Data Security and Protection Toolkit - NHS Digital. NHS Digital (Now NHS England). https:\/\/digital.nhs.uk\/data-and-information\/looking-after-information\/data-security-and-information-governance\/data-security-and-protection-toolkit (accessed 4 July 2023)."},{"key":"e_1_3_3_33_2","unstructured":"ISB1523: Anonymisation Standard for Publishing Health and Social Care Data. NHS Digital (Now NHS England). https:\/\/digital.nhs.uk\/data-and-information\/information-standards\/information-standards-and-data-collections-including-extractions\/publications-and-notifications\/standards-and-collections\/isb1523-anonymisation-standard-for-publishing-health-and-social-care-data (accessed 4 July 2023)."},{"key":"e_1_3_3_34_2","unstructured":"Coronavirus (COVID-19): notice under regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 \u2013 general. 2022. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-notification-of-data-controllers-to-share-information\/coronavirus-covid-19-notice-under-regulation-34-of-the-health-service-control-of-patient-information-regulations-2002-general\u20132 (accessed 5 July 2023)."},{"key":"e_1_3_3_35_2","unstructured":"Secretary of State for Health and Social Care - UK Government. COVID-19 Public Health Directions 2020: notification to NHS Digital. https:\/\/digital.nhs.uk\/about-nhs-digital\/corporate-information-and-documents\/directions-and-data-provision-notices\/secretary-of-state-directions\/covid-19-public-health-directions-2020 (accessed 4 July 2023)."},{"key":"e_1_3_3_36_2","unstructured":"Confidentiality Advisory Group. Health Research Authority. https:\/\/www.hra.nhs.uk\/about-us\/committees-and-services\/confidentiality-advisory-group\/ (accessed 4 July 2023)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261436698","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261436698","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261436698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:36Z","timestamp":1777689156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261436698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":35,"alternative-id":["10.1177\/10781552261436698"],"URL":"https:\/\/doi.org\/10.1177\/10781552261436698","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"article-number":"10781552261436698"}}